```
=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 ful
FULL SEARCH INITIATED 11:49:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       86 TO ITERATE

100.0% PROCESSED       86 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

L2            1 SEA SSS FUL L1

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   863203-44-5  REGISTRY
ED   Entered STN:  15 Sep 2005
CN   Benzenepropanoic acid, β-[[[2,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-
     2-aziridinyl]carbonyl]amino]-α-hydroxy-,
     (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
     2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
     tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
     ester, (αR,βS)-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C52 H60 N2 O16 S
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry.
```



```
              2 REFERENCES IN FILE CA (1907 TO DATE)
              2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> fil caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               180.36     180.57

FILE 'CAPLUS' ENTERED AT 11:49:32 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 13 Sep 2008  VOL 149 ISS 12
FILE LAST UPDATED: 12 Sep 2008  (20080912/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3            2 L2

=> d 1-2 bib abs hitstr

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:979631  CAPLUS <<LOGINID::20080913>>
DN   143:267122
TI   Semi-synthesis of taxane intermediates and aziridine analogs and their
     conversion to paclitaxel and docetaxel
IN   Naidu, Ragina
PA   Phytogen Life Sciences Inc., Can.; Phytogen Inc.
SO   PCT Int. Appl., 37 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
```

PI	WO 2005082875	A2	20050909	WO 2005-US5953	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050192445	A1	20050901	US 2004-790622	20040301
	CA 2598707	A1	20050909	CA 2005-2598707	20050224
	EP 1732911	A2	20061220	EP 2005-723708	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1942458	A	20070404	CN 2005-80008412	20050224
	US 20080033189	A1	20080207	US 2007-590647	20070720
PRAI	US 2004-785422	A	20040224		
	US 2004-790622	A	20040301		
	WO 2005-US5953	W	20050224		
OS	CASREACT 143:267122; MARPAT 143:267122				
GI					



I



II

AB A process is provided for the semi-synthesis of taxane intermediates I [R = H, O-protecting group] and aziridine analogs II of cephalomannine and intermediates of baccatin III , and the conversion of such intermediates and analogs to paclitaxel and docetaxel. One process comprises: (a) conversion of the side chain of cephalomannine to an aziridine; (b) hydrolysis of the side chain. Another process comprises: (a) preparation of N-tosyl-3-phenylaziridine-3-carbonyl chloride or 2-acetoxy-3-phenyl-3-(tosylamino)propionyl chloride from cinnamoyl chloride; (b) acylation of 7-O-protected baccatin III by the carbonyl chlorides; and (c) acetolysis followed by hydrolysis of the former or hydrolysis of the latter intermediate. A third process comprises: (a) epoxidn. of the side chain of cephalomannine; (b) azidolysis of the side chain epoxide; (c) hydrolysi of the side chain.

IT 863203-44-5DP, 7,2'-O-derivs.
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and basic hydrolysis of; semi-synthesis of taxane intermediates and aziridine analogs and their conversion to paclitaxel and docetaxel)

RN 863203-44-5 CAPLUS

CN Benzenepropanoic acid, β-[[[2,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-2-aziridinyl]carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:963841 CAPLUS <<LOGINID::20080913>>

DN 143:248536

TI Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel

IN Naidu, Ragina

PA Phytogen Life Sciences Inc., Can.
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050192445	A1	20050901	US 2004-790622	20040301
	CA 2598707	A1	20050909	CA 2005-2598707	20050224
	WO 2005082875	A2	20050909	WO 2005-US5953	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1732911	A2	20061220	EP 2005-723708	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1942458	A	20070404	CN 2005-80008412	20050224
	US 20070027331	A1	20070201	US 2006-372476	20060309
	US 20080033189	A1	20080207	US 2007-590647	20070720
PRAI	US 2004-785422	A	20040224		
	US 2004-790622	A	20040301		
	WO 2005-US5953	W	20050224		

OS CASREACT 143:248536; MARPAT 143:248536
GI



I

AB A process is provided for the semi-synthesis of taxane intermediates and aziridine analogs (e.g. formula I [R = H, protecting group]) of cephalomannine and baccatin III intermediates, and the conversion of such intermediates and analogs to paclitaxel and docetaxel (no data).

IT 863203-44-5DP, protected
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(semi-synthesis of taxane intermediates and aziridine analogs and their conversion to paclitaxel and docetaxel)

RN 863203-44-5 CAPLUS

CN Benzenepropanoic acid, β-[[[2,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-2-aziridinyl]carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.86	192.43
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'REGISTRY' ENTERED AT 11:51:00 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 SEP 2008 HIGHEST RN 1049105-01-2
DICTIONARY FILE UPDATES: 12 SEP 2008 HIGHEST RN 1049105-01-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\rkc647b.str



chain nodes :
12 13 20 21 22 23 24 25 26 27 28 29 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18 19 32 33 34
chain bonds :
3-23 6-13 7-24 7-25 8-12 9-21 11-22 14-20 16-26 22-27 27-28 28-29 29-30
30-31 31-32
ring bonds :
1-2 1-7 1-9 2-3 3-4 4-5 4-14 5-6 5-16 6-8 7-8 8-10 9-11 10-11 14-15
15-17 16-17 16-18 17-19 18-19 32-33 32-34 33-34
exact/norm bonds :
1-2 1-7 1-9 2-3 3-4 3-23 4-5 4-14 5-6 5-16 6-8 6-13 7-8 8-10 8-12
9-11 10-11 11-22 14-15 14-20 15-17 16-17 16-18 16-26 17-19 18-19 22-27
29-30 30-31 32-33
32-34 33-34
exact bonds :
7-24 7-25 9-21 27-28 28-29 31-32

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:CLASS  13:CLASS  14:Atom  15:Atom  16:Atom  17:Atom  18:CLASS  19:Atom
20:CLASS  21:CLASS
22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS  29:CLASS
30:CLASS  31:CLASS
32:Atom  33:Atom  34:Atom



L4      STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l4 ful
FULL SEARCH INITIATED 11:52:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       48 TO ITERATE
```

```
100.0% PROCESSED       48 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01

L5            1 SEA SSS FUL L4

=> d

L5   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   863203-44-5  REGISTRY
ED   Entered STN:  15 Sep 2005
CN   Benzenepropanoic acid, β-[[[2,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-
     2-aziridinyl]carbonyl]amino]-α-hydroxy-,
     (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
     2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
     tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
     ester, (αR,βS)-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C52 H60 N2 O16 S
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry.
```




```
                2 REFERENCES IN FILE CA (1907 TO DATE)
                2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
                2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> fil caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                180.82     373.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
```

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'CAPLUS' ENTERED AT 11:52:25 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Sep 2008 VOL 149 ISS 12
FILE LAST UPDATED: 12 Sep 2008 (20080912/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l5
L6           2 L5

=> d 1-2 bib abs

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:979631  CAPLUS <<LOGINID::20080913>>
DN   143:267122
TI   Semi-synthesis of taxane intermediates and aziridine analogs and their
     conversion to paclitaxel and docetaxel
IN   Naidu, Ragina
PA   Phytogen Life Sciences Inc., Can.; Phytogen Inc.
SO   PCT Int. Appl., 37 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005082875        A2    20050909    WO 2005-US5953         20050224
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
            SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
```

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	20050192445	A1	20050901	US 2004-790622	20040301
CA	2598707	A1	20050909	CA 2005-2598707	20050224
EP	1732911	A2	20061220	EP 2005-723708	20050224
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN	1942458	A	20070404	CN 2005-80008412	20050224
US	20080033189	A1	20080207	US 2007-590647	20070720

PRAI US 2004-785422 A 20040224
US 2004-790622 A 20040301
WO 2005-US5953 W 20050224

OS CASREACT 143:267122; MARPAT 143:267122

GI



I



II

AB A process is provided for the semi-synthesis of taxane intermediates I [R = H, O-protecting group] and aziridine analogs II of cephalomannine and intermediates of baccatin III , and the conversion of such intermediates and analogs to paclitaxel and docetaxel. One process comprises: (a) conversion of the side chain of cephalomannine to an aziridine; (b) hydrolysis of the side chain. Another process comprises: (a) preparation of N-tosyl-3-phenylaziridine-3-carbonyl chloride or 2-acetoxy-3-phenyl-3-

(tosylamino)propionyl chloride from cinnamoyl chloride; (b) acylation of 7-O-protected baccatin III by the carbonyl chlorides; and (c) acetolysis followed by hydrolysis of the former or hydrolysis of the latter intermediate. A third process comprises: (a) epoxidn. of the side chain of cephalomannine; (b) azidolysis of the side chain epoxide; (c) hydrolysi of the side chain.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:963841 CAPLUS <<LOGINID::20080913>>
DN 143:248536
TI Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050192445	A1	20050901	US 2004-790622	20040301
	CA 2598707	A1	20050909	CA 2005-2598707	20050224
	WO 2005082875	A2	20050909	WO 2005-US5953	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1732911	A2	20061220	EP 2005-723708	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1942458	A	20070404	CN 2005-80008412	20050224
	US 20070027331	A1	20070201	US 2006-372476	20060309
	US 20080033189	A1	20080207	US 2007-590647	20070720
PRAI	US 2004-785422	A	20040224		
	US 2004-790622	A	20040301		
	WO 2005-US5953	W	20050224		

OS CASREACT 143:248536; MARPAT 143:248536
GI



I

AB A process is provided for the semi-synthesis of taxane intermediates and aziridine analogs (e.g. formula I [R = H, protecting group]) of cephalomannine and baccatin III intermediates, and the conversion of such intermediates and analogs to paclitaxel and docetaxel (no data).

```
=> s taxane and aziridine
          3442 TAXANE
          9474 AZIRIDINE
L7           6 TAXANE AND AZIRIDINE

=> d 1-6 bib abs hitstr

L7   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:1053651  CAPLUS <<LOGINID::20080913>>
DN   147:378345
TI   Anticancer activity augmentation dithio compounds, formulations, and
     methods of use
IN   Hausheer, Frederick H.
PA   Bionumerik Pharmaceuticals, Inc., USA
SO   U.S. Pat. Appl. Publ., 35pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   US 20070219268       A1    20070920    US 2007-724933          20070316
     WO 2007109184        A2    20070927    WO 2007-US6725          20070316
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
             KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2006-782826P      P     20060316
```

AB The field of the invention comprises pharmaceuticals and pharmaceutical treatments, including e.g. (i) compds. and formulations which cause the augmentation of anticancer activity (i.e., by enhancement of the lethal cytotoxic action in stimulatory [inducing oxidative stress] and/or depletive [decreasing antioxidative capacity] manner) of chemotherapeutic agents, in a selective manner; (ii) methods for administering the anticancer augmentation compds. and formulations; (iii) delivery devices containing the anti-cancer augmentation compds. and formulations; and (iv) methods for using the anticancer augmentation compds., formulations, and devices to treat subjects in need thereof. Compds. of the invention include dithio compds.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1357176 CAPLUS <<LOGINID::20080913>>
DN 146:100684
TI Pyrazole derivatives as protein kinase modulators, their preparation, pharmaceutical compositions, and use in therapy
IN Thompson, Neil Thomas; Boyle, Robert George; Collins, Ian; Garrett, Michelle Dawn; Lyons, John Francis; Thompson, Kyla Merriom
PA Astex Therapeutics Limited, UK; The Institute of Cancer ResearchRoyal Cancer Hospital; Cancer Research Technology Limited
SO PCT Int. Appl., 226pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006136837	A2	20061228	WO 2006-GB2297	20060621
	WO 2006136837	A3	20070215		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1933832	A2	20080625	EP 2006-755597	20060621
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2005-693309P	P	20050623		
	US 2005-693314P	P	20050623		
	US 2005-693315P	P	20050623		
	US 2005-693367P	P	20050623		
	US 2005-693492P	P	20050623		
	WO 2006-GB2297	W	20060621		

OS MARPAT 146:100684
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to pyrazole derivs. of formula I, which are modulators of protein kinase B (PKB) and protein kinase A (PKA). In compds. I, L is C1-7 alkylene containing no more than 5 carbon atoms between R1 and NR2R3 and no more than 4 carbon atoms between E and NR2R3, where one of the carbon atoms may be replaced by O or N; E is mono- or bicyclic carbocyclyl or heterocyclyl; R1 is aryl or heteroaryl; R2 and R3 are independently selected from H, (un)substituted C1-4 alkyl, and (un)substituted C1-4 acyl, or R2 and R3, together with the nitrogen atom to which they are attached, form a cyclic group selected from imidazole and 4- to 7-membered monocyclic heterocyclyl, optionally containing another heteroatom selected from O and N, or NR2R3 and the adjacent carbon atom from L together form a cyano group; R4 is selected from H, halo, cyano, CF3, C1-5 alkyl, and C1-5 alkoxy; and R5 is selected from H, halo, cyano, amino, CF3, C1-5 alkyl, C1-5 alkoxy, (un)substituted carbamoyl, acylamino, and ureido. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound of formula I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment or prophylaxis of diseases or conditions mediated by PKB or PKA. Also provided are patient packs, pharmaceutical kits and packs and compns. containing the combinations, methods for preparing the combinations and their use
in combination therapy as anticancer agents. Addition of 4-chlorophenylmagnesium bromide to 4-bromobenzaldehyde followed by coupling with N-(2-hydroxyethyl)phthalimide gave benzhydryl ether II, which underwent Suzuki coupling with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and cleavage to give amine III. Several compds. of the invention express IC50 values of less than 1 μM to PKA or PKB, or both, e.g., III.

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:275458 CAPLUS <<LOGINID::20080913>>
DN 144:325290
TI GLP-1 and exendin derivatives for disease diagnosis and treatment
IN Gotthardt, Martin; Behe, Martin; Behr, Thomas; Goeke, Burkhard J.
PA Transmit Gesellschaft fuer Technologietransfer m.b.H., Germany
SO Ger. Offen., 17 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004043153	A1	20060323	DE 2004-102004043153	20040903
	AU 2005279537	A1	20060309	AU 2005-279537	20050826
	CA 2578252	A1	20060309	CA 2005-2578252	20050826
	WO 2006024275	A2	20060309	WO 2005-DE1503	20050826
	WO 2006024275	A3	20061130		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,

ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1784422	A2	20070516	EP 2005-778889	20050826
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101010340	A	20070801	CN 2005-80029760	20050826
JP 2008511557	T	20080417	JP 2007-528593	20050826
BR 2005015624	A	20080729	BR 2005-15624	20050826
MX 200702455	A	20071010	MX 2007-2455	20070228
IN 2007KN01064	A	20070713	IN 2007-KN1064	20070326
NO 2007001592	A	20070529	NO 2007-1592	20070327
KR 2007093960	A	20070919	KR 2007-707577	20070402
PRAI DE 2004-102004043153	A	20040903		
WO 2005-DE1503	W	20050826		

AB GLP-1 (glucagon-like peptide 1) and exendin-3 and/or exendin-4 derivs. are disclosed which may be used for disease diagnosis and treatment. The peptides, or fragments thereof, are conjugated to an amine-containing compound at the C-terminus, e.g., lysine or ornithine. The amine function is used to attach a desired functional moiety, e.g, a metal chelator, a fluorophore, a pharmaceutical. The C-terminal conjugation does not inhibit binding of the GLP-1 or exendins to their receptors. Thus, a complex of In111 with 7-36-GLP-1-Lys(DTPA)NH2, i.e., residues 7-36 of human GLP-1 with L-lysinamide attached to the C-terminus and the chelator DTPA attached to the ε-amino group of lysine, was prepared This complex localized to GLP-1 receptor-bearing tumors in mice.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:979631 CAPLUS <<LOGINID::20080913>>
DN 143:267122
TI Semi-synthesis of taxane intermediates and aziridine analogs and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.; Phytogen Inc.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005082875	A2	20050909	WO 2005-US5953	20050224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG
US 20050192445 A1 20050901 US 2004-790622 20040301
CA 2598707 A1 20050909 CA 2005-2598707 20050224
EP 1732911 A2 20061220 EP 2005-723708 20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 1942458 A 20070404 CN 2005-80008412 20050224
US 20080033189 A1 20080207 US 2007-590647 20070720
PRAI US 2004-785422 A 20040224
US 2004-790622 A 20040301
WO 2005-US5953 W 20050224
OS CASREACT 143:267122; MARPAT 143:267122
GI



I



II

AB A process is provided for the semi-synthesis of taxane intermediates I [R = H, O-protecting group] and aziridine analogs II of cephalomannine and intermediates of baccatin III , and the conversion of such intermediates and analogs to paclitaxel and docetaxel. One process comprises: (a) conversion of the side chain of cephalomannine to an aziridine; (b) hydrolysis of the side chain. Another process comprises: (a) preparation of N-tosyl-3-phenylaziridine-3-carbonyl chloride or 2-acetoxy-3-phenyl-3-(tosylamino)propionyl chloride from cinnamoyl chloride; (b) acylation of 7-O-protected baccatin III by the carbonyl chlorides; and (c) acetolysis followed by hydrolysis of the former or hydrolysis of the latter intermediate. A third process

comprises: (a) epoxidn. of the side chain of cephalomannine; (b) azidolysis of the side chain epoxide; (c) hydrolysi of the side chain.

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:963841 CAPLUS <<LOGINID::20080913>>
DN 143:248536
TI Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050192445	A1	20050901	US 2004-790622	20040301
	CA 2598707	A1	20050909	CA 2005-2598707	20050224
	WO 2005082875	A2	20050909	WO 2005-US5953	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1732911	A2	20061220	EP 2005-723708	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1942458	A	20070404	CN 2005-80008412	20050224
	US 20070027331	A1	20070201	US 2006-372476	20060309
	US 20080033189	A1	20080207	US 2007-590647	20070720
PRAI	US 2004-785422	A	20040224		
	US 2004-790622	A	20040301		
	WO 2005-US5953	W	20050224		

OS CASREACT 143:248536; MARPAT 143:248536
GI



I

AB A process is provided for the semi-synthesis of taxane intermediates and aziridine analogs (e.g. formula I [R = H, protecting group]) of cephalomannine and baccatin III intermediates, and the conversion of such intermediates and analogs to paclitaxel and docetaxel (no data).

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:256023 CAPLUS <<LOGINID::20080913>>
DN 136:299699
TI Emulsion vehicle for poorly soluble drugs
IN Constantinides, Panayiotis P.; Lambert, Karel J.; Tustian, Alexander K.; Nienstedt, Andrew M.; Hartgraves, Greg A.
PA Sonus Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002026208	A2	20020404	WO 2001-US30471	20010927
	WO 2002026208	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001093177	A	20020408	AU 2001-93177	20010927
PRAI	US 2000-670627	A1	20000927		
	WO 2001-US30471	W	20010927		

AB Pharmaceutical compns. contain one or more therapeutics or chemotherapeutics, one or more tocols as a solvent, a surfactant, and optionally a co-solvent. An example was given in which paclitaxel was solubilized with α-tocopherol.

```
=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 ful
FULL SEARCH INITIATED 11:49:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       86 TO ITERATE

100.0% PROCESSED       86 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

L2            1 SEA SSS FUL L1

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   863203-44-5  REGISTRY
ED   Entered STN:  15 Sep 2005
CN   Benzenepropanoic acid, β-[[[2,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-
     2-aziridinyl]carbonyl]amino]-α-hydroxy-,
     (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
     2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
     tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
     ester, (αR,βS)-  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C52 H60 N2 O16 S
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry.
```



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	180.36	180.57

FILE 'CAPLUS' ENTERED AT 11:49:32 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Sep 2008 VOL 149 ISS 12
FILE LAST UPDATED: 12 Sep 2008 (20080912/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2
L3 2 L2

=> d l-2 bib abs hitstr

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:979631 CAPLUS
DN 143:267122
TI Semi-synthesis of taxane intermediates and aziridine analogs and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.; Phytogen Inc.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005082875	A2	20050909	WO 2005-US5953	20050224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	20050192445	A1	20050901	US 2004-790622	20040301
CA	2598707	A1	20050909	CA 2005-2598707	20050224
EP	1732911	A2	20061220	EP 2005-723708	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN	1942458	A	20070404	CN 2005-80008412	20050224
US	20080033189	A1	20080207	US 2007-590647	20070720
PRAI US	2004-785422	A	20040224		
US	2004-790622	A	20040301		
WO	2005-US5953	W	20050224		

OS CASREACT 143:267122; MARPAT 143:267122

GI



I



II

AB A process is provided for the semi-synthesis of taxane intermediates I [R = H, O-protecting group] and aziridine analogs II of cephalomannine and intermediates of baccatin III , and the conversion of such intermediates

and analogs to paclitaxel and docetaxel. One process comprises: (a) conversion of the side chain of cephalomannine to an aziridine; (b) hydrolysis of the side chain. Another process comprises: (a) preparation of N-tosyl-3-phenylaziridine-3-carbonyl chloride or 2-acetoxy-3-phenyl-3-(tosylamino)propionyl chloride from cinnamoyl chloride; (b) acylation of 7-O-protected baccatin III by the carbonyl chlorides; and (c) acetolysis followed by hydrolysis of the former or hydrolysis of the latter intermediate. A third process comprises: (a) epoxidn. of the side chain of cephalomannine; (b) azidolysis of the side chain epoxide; (c) hydrolysi of the side chain.

IT 863203-44-5DP, 7,2'-O-derivs.
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and basic hydrolysis of; semi-synthesis of taxane intermediates and aziridine analogs and their conversion to paclitaxel and docetaxel)

RN 863203-44-5 CAPLUS

CN Benzenepropanoic acid, β-[[[2,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-2-aziridinyl]carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:963841 CAPLUS
DN 143:248536
TI Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050192445	A1	20050901	US 2004-790622	20040301
	CA 2598707	A1	20050909	CA 2005-2598707	20050224
	WO 2005082875	A2	20050909	WO 2005-US5953	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1732911	A2	20061220	EP 2005-723708	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1942458	A	20070404	CN 2005-80008412	20050224
	US 20070027331	A1	20070201	US 2006-372476	20060309
	US 20080033189	A1	20080207	US 2007-590647	20070720
PRAI	US 2004-785422	A	20040224		
	US 2004-790622	A	20040301		
	WO 2005-US5953	W	20050224		

OS CASREACT 143:248536; MARPAT 143:248536

GI



I

AB A process is provided for the semi-synthesis of taxane intermediates and aziridine analogs (e.g. formula I [R = H, protecting group]) of cephalomannine and baccatin III intermediates, and the conversion of such intermediates and analogs to paclitaxel and docetaxel (no data).

IT 863203-44-5DP, protected
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(semi-synthesis of taxane intermediates and aziridine analogs and their conversion to paclitaxel and docetaxel)

RN 863203-44-5 CAPLUS

CN Benzenepropanoic acid, β-[[[2,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-2-aziridinyl]carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl

ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.86	192.43
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

FILE 'REGISTRY' ENTERED AT 11:51:00 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 SEP 2008 HIGHEST RN 1049105-01-2
DICTIONARY FILE UPDATES: 12 SEP 2008 HIGHEST RN 1049105-01-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\rkc647b.str



chain nodes :
12 13 20 21 22 23 24 25 26 27 28 29 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18 19 32 33 34
chain bonds :
3-23 6-13 7-24 7-25 8-12 9-21 11-22 14-20 16-26 22-27 27-28 28-29 29-30
30-31 31-32
ring bonds :
1-2 1-7 1-9 2-3 3-4 4-5 4-14 5-6 5-16 6-8 7-8 8-10 9-11 10-11 14-15
15-17 16-17 16-18 17-19 18-19 32-33 32-34 33-34
exact/norm bonds :
1-2 1-7 1-9 2-3 3-4 3-23 4-5 4-14 5-6 5-16 6-8 6-13 7-8 8-10 8-12
9-11 10-11 11-22 14-15 14-20 15-17 16-17 16-18 16-26 17-19 18-19 22-27
29-30 30-31 32-33 32-34 33-34
exact bonds :
7-24 7-25 9-21 27-28 28-29 31-32

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:Atom 33:Atom 34:Atom

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4 ful
FULL SEARCH INITIATED 11:52:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 48 TO ITERATE

100.0% PROCESSED 48 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L5 1 SEA SSS FUL L4

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 863203-44-5 REGISTRY
ED Entered STN: 15 Sep 2005
CN Benzenepropanoic acid, β-[[[2,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-2-aziridinyl]carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

FS STEREOSEARCH
MF C52 H60 N2 O16 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	180.82	373.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.60

FILE 'CAPLUS' ENTERED AT 11:52:25 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

```
FILE COVERS 1907 - 13 Sep 2008  VOL 149 ISS 12
FILE LAST UPDATED: 12 Sep 2008  (20080912/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l5
L6            2 L5

=> d 1-2 bib abs

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:979631  CAPLUS
DN   143:267122
TI   Semi-synthesis of taxane intermediates and aziridine analogs and their
     conversion to paclitaxel and docetaxel
IN   Naidu, Ragina
PA   Phytogen Life Sciences Inc., Can.; Phytogen Inc.
SO   PCT Int. Appl., 37 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------          ----   --------    -------------------    --------
PI   WO 2005082875       A2     20050909    WO 2005-US5953         20050224
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     US 20050192445       A1     20050901    US 2004-790622         20040301
     CA 2598707           A1     20050909    CA 2005-2598707        20050224
     EP 1732911           A2     20061220    EP 2005-723708         20050224
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     CN 1942458           A      20070404    CN 2005-80008412       20050224
     US 20080033189       A1     20080207    US 2007-590647         20070720
PRAI US 2004-785422       A      20040224
     US 2004-790622       A      20040301
     WO 2005-US5953       W      20050224
OS   CASREACT 143:267122; MARPAT 143:267122
GI
```



I



II

AB A process is provided for the semi-synthesis of taxane intermediates I [R = H, O-protecting group] and aziridine analogs II of cephalomannine and intermediates of baccatin III , and the conversion of such intermediates and analogs to paclitaxel and docetaxel. One process comprises: (a) conversion of the side chain of cephalomannine to an aziridine; (b) hydrolysis of the side chain. Another process comprises: (a) preparation of N-tosyl-3-phenylaziridine-3-carbonyl chloride or 2-acetoxy-3-phenyl-3-(tosylamino)propionyl chloride from cinnamoyl chloride; (b) acylation of 7-O-protected baccatin III by the carbonyl chlorides; and (c) acetolysis followed by hydrolysis of the former or hydrolysis of the latter intermediate. A third process comprises: (a) epoxidn. of the side chain of cephalomannine; (b) azidolysis of the side chain epoxide; (c) hydrolysi of the side chain.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:963841 CAPLUS
DN 143:248536
TI Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
PI   US 20050192445          A1     20050901    US 2004-790622          20040301
     CA 2598707              A1     20050909    CA 2005-2598707         20050224
     WO 2005082875           A2     20050909    WO 2005-US5953          20050224
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
              SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
              RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
              MR, NE, SN, TD, TG
     EP 1732911              A2     20061220    EP 2005-723708          20050224
          R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     CN 1942458              A      20070404    CN 2005-80008412        20050224
     US 20070027331          A1     20070201    US 2006-372476          20060309
     US 20080033189          A1     20080207    US 2007-590647          20070720
PRAI US 2004-785422          A      20040224
     US 2004-790622          A      20040301
     WO 2005-US5953          W      20050224
OS   CASREACT 143:248536; MARPAT 143:248536
GI
```



I

AB A process is provided for the semi-synthesis of taxane intermediates and aziridine analogs (e.g. formula I [R = H, protecting group]) of cephalomannine and baccatin III intermediates, and the conversion of such intermediates and analogs to paclitaxel and docetaxel (no data).

```
=> s taxane and aziridine
          3442 TAXANE
          9474 AZIRIDINE
L7           6 TAXANE AND AZIRIDINE

=> d 1-6 bib abs hitstr

L7   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2007:1053651  CAPLUS
DN   147:378345
TI   Anticancer activity augmentation dithio compounds, formulations, and
```

methods of use
IN Hausheer, Frederick H.
PA Bionumerik Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 35pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070219268	A1	20070920	US 2007-724933	20070316
WO 2007109184	A2	20070927	WO 2007-US6725	20070316

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2006-782826P P 20060316
AB The field of the invention comprises pharmaceuticals and pharmaceutical treatments, including e.g. (i) compds. and formulations which cause the augmentation of anticancer activity (i.e., by enhancement of the lethal cytotoxic action in stimulatory [inducing oxidative stress] and/or depletive [decreasing antioxidative capacity] manner) of chemotherapeutic agents, in a selective manner; (ii) methods for administering the anticancer augmentation compds. and formulations; (iii) delivery devices containing the anti-cancer augmentation compds. and formulations; and (iv) methods for using the anticancer augmentation compds., formulations, and devices to treat subjects in need thereof. Compds. of the invention include dithio compds.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1357176 CAPLUS
DN 146:100684
TI Pyrazole derivatives as protein kinase modulators, their preparation, pharmaceutical compositions, and use in therapy
IN Thompson, Neil Thomas; Boyle, Robert George; Collins, Ian; Garrett, Michelle Dawn; Lyons, John Francis; Thompson, Kyla Merriom
PA Astex Therapeutics Limited, UK; The Institute of Cancer ResearchRoyal Cancer Hospital; Cancer Research Technology Limited
SO PCT Int. Appl., 226pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006136837	A2	20061228	WO 2006-GB2297	20060621
WO 2006136837	A3	20070215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
EP 1933832 A2 20080625 EP 2006-755597 20060621
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
PRAI US 2005-693309P P 20050623
US 2005-693314P P 20050623
US 2005-693315P P 20050623
US 2005-693367P P 20050623
US 2005-693492P P 20050623
WO 2006-GB2297 W 20060621
OS MARPAT 146:100684
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to pyrazole derivs. of formula I, which are modulators of protein kinase B (PKB) and protein kinase A (PKA). In compds. I, L is C1-7 alkylene containing no more than 5 carbon atoms between R1 and NR2R3 and no more than 4 carbon atoms between E and NR2R3, where one of the carbon atoms may be replaced by O or N; E is mono- or bicyclic carbocyclyl or heterocyclyl; R1 is aryl or heteroaryl; R2 and R3 are independently selected from H, (un)substituted C1-4 alkyl, and (un)substituted C1-4 acyl, or R2 and R3, together with the nitrogen atom to which they are attached, form a cyclic group selected from imidazole and 4- to 7-membered monocyclic heterocyclyl, optionally containing another heteroatom selected from O and N, or NR2R3 and the adjacent carbon atom from L together form a cyano group; R4 is selected from H, halo, cyano, CF3, C1-5 alkyl, and C1-5 alkoxy; and R5 is selected from H, halo, cyano, amino, CF3, C1-5 alkyl, C1-5 alkoxy, (un)substituted carbamoyl, acylamino, and ureido. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound of formula I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment or prophylaxis of diseases or conditions mediated by PKB or PKA. Also provided are patient packs, pharmaceutical kits and packs and compns. containing the combinations, methods for preparing the combinations and their use
in combination therapy as anticancer agents. Addition of 4-chlorophenylmagnesium bromide to 4-bromobenzaldehyde followed by coupling with N-(2-hydroxyethyl)phthalimide gave benzhydryl ether II, which underwent Suzuki coupling with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and cleavage to give amine III. Several compds. of the invention express IC50 values of less than 1 μM to PKA or PKB, or both, e.g., III.

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:275458 CAPLUS
DN 144:325290
TI GLP-1 and exendin derivatives for disease diagnosis and treatment
IN Gotthardt, Martin; Behe, Martin; Behr, Thomas; Goeke, Burkhard J.
PA Transmit Gesellschaft fuer Technologietransfer m.b.H., Germany
SO Ger. Offen., 17 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004043153	A1	20060323	DE 2004-102004043153	20040903
	AU 2005279537	A1	20060309	AU 2005-279537	20050826
	CA 2578252	A1	20060309	CA 2005-2578252	20050826
	WO 2006024275	A2	20060309	WO 2005-DE1503	20050826
	WO 2006024275	A3	20061130		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1784422	A2	20070516	EP 2005-778889	20050826
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101010340	A	20070801	CN 2005-80029760	20050826
	JP 2008511557	T	20080417	JP 2007-528593	20050826
	BR 2005015624	A	20080729	BR 2005-15624	20050826
	MX 200702455	A	20071010	MX 2007-2455	20070228
	IN 2007KN01064	A	20070713	IN 2007-KN1064	20070326
	NO 2007001592	A	20070529	NO 2007-1592	20070327
	KR 2007093960	A	20070919	KR 2007-707577	20070402
PRAI	DE 2004-102004043153	A	20040903		
	WO 2005-DE1503	W	20050826		

AB GLP-1 (glucagon-like peptide 1) and exendin-3 and/or exendin-4 derivs. are disclosed which may be used for disease diagnosis and treatment. The peptides, or fragments thereof, are conjugated to an amine-containing compound at the C-terminus, e.g., lysine or ornithine. The amine function is used to attach a desired functional moiety, e.g, a metal chelator, a fluorophore, a pharmaceutical. The C-terminal conjugation does not inhibit binding of the GLP-1 or exendins to their receptors. Thus, a complex of In111 with 7-36-GLP-1-Lys(DTPA)NH2, i.e., residues 7-36 of human GLP-1 with L-lysinamide attached to the C-terminus and the chelator DTPA attached to the ε-amino group of lysine, was prepared This complex localized to GLP-1 receptor-bearing tumors in mice.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:979631 CAPLUS
DN 143:267122
TI Semi-synthesis of taxane intermediates and aziridine analogs and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.; Phytogen Inc.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082875	A2	20050909	WO 2005-US5953	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050192445	A1	20050901	US 2004-790622	20040301
	CA 2598707	A1	20050909	CA 2005-2598707	20050224
	EP 1732911	A2	20061220	EP 2005-723708	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1942458	A	20070404	CN 2005-80008412	20050224
	US 20080033189	A1	20080207	US 2007-590647	20070720
PRAI	US 2004-785422	A	20040224		
	US 2004-790622	A	20040301		
	WO 2005-US5953	W	20050224		

OS CASREACT 143:267122; MARPAT 143:267122
GI



I



II

AB A process is provided for the semi-synthesis of taxane intermediates I [R = H, O-protecting group] and aziridine analogs II of cephalomannine and intermediates of baccatin III , and the conversion of such intermediates and analogs to paclitaxel and docetaxel. One process comprises: (a) conversion of the side chain of cephalomannine to an aziridine; (b) hydrolysis of the side chain. Another process comprises: (a) preparation of N-tosyl-3-phenylaziridine-3-carbonyl chloride or 2-acetoxy-3-phenyl-3-(tosylamino)propionyl chloride from cinnamoyl chloride; (b) acylation of 7-O-protected baccatin III by the carbonyl chlorides; and (c) acetolysis followed by hydrolysis of the former or hydrolysis of the latter intermediate. A third process comprises: (a) epoxidn. of the side chain of cephalomannine; (b) azidolysis of the side chain epoxide; (c) hydrolysi of the side chain.

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:963841 CAPLUS
DN 143:248536
TI Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050192445	A1	20050901	US 2004-790622	20040301

CA 2598707 A1 20050909 CA 2005-2598707 20050224
WO 2005082875 A2 20050909 WO 2005-US5953 20050224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1732911 A2 20061220 EP 2005-723708 20050224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 1942458 A 20070404 CN 2005-80008412 20050224
US 20070027331 A1 20070201 US 2006-372476 20060309
US 20080033189 A1 20080207 US 2007-590647 20070720
PRAI US 2004-785422 A 20040224
US 2004-790622 A 20040301
WO 2005-US5953 W 20050224
OS CASREACT 143:248536; MARPAT 143:248536
GI



I

AB A process is provided for the semi-synthesis of taxane intermediates and aziridine analogs (e.g. formula I [R = H, protecting group]) of cephalomannine and baccatin III intermediates, and the conversion of such intermediates and analogs to paclitaxel and docetaxel (no data).

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:256023 CAPLUS
DN 136:299699
TI Emulsion vehicle for poorly soluble drugs
IN Constantinides, Panayiotis P.; Lambert, Karel J.; Tustian, Alexander K.; Nienstedt, Andrew M.; Hartgraves, Greg A.
PA Sonus Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent

```
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
PI   WO 2002026208        A2    20020404    WO 2001-US30471          20010927
     WO 2002026208        A3    20030123
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2001093177         A     20020408    AU 2001-93177            20010927
PRAI US 2000-670627        A1    20000927
     WO 2001-US30471       W     20010927
AB   Pharmaceutical compns. contain one or more therapeutics or
     chemotherapeutics, one or more tocols as a solvent, a surfactant, and
     optionally a co-solvent.  An example was given in which paclitaxel was
     solubilized with α-tocopherol.


=>

=>
Executing the logoff script...


=> LOG H

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    32.80     406.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -6.40      -8.00

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:59:15 ON 13 SEP 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:sssptau129rc

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 12:02:46 ON 13 SEP 2008
FILE 'CAPLUS' ENTERED AT 12:02:46 ON 13 SEP 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                32.80     406.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -6.40      -8.00

=> fil reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                34.24     407.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -6.40      -8.00

FILE 'REGISTRY' ENTERED AT 12:04:21 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 SEP 2008  HIGHEST RN 1049105-01-2
DICTIONARY FILE UPDATES:  12 SEP 2008  HIGHEST RN 1049105-01-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\rkc647c.str
```



```
chain nodes :
4  5  6  7
ring nodes :
1  2  3
chain bonds :
1-4  3-5  5-6  5-7
ring bonds :
1-3  1-2  2-3
exact/norm bonds :
1-3  1-2  2-3  5-6
exact bonds :
1-4  3-5  5-7


Match level :
1:Atom  2:Atom  3:Atom  4:CLASS  5:CLASS  6:CLASS  7:CLASS



L8      STRUCTURE UPLOADED

=> d
L8 HAS NO ANSWERS
L8                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l8 ful
FULL SEARCH INITIATED 12:04:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       47 TO ITERATE

100.0% PROCESSED       47 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

L9            1 SEA SSS FUL L8

=> d 1

L9   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   863203-37-6  REGISTRY
ED   Entered STN:  15 Sep 2005
```

CN 2-Aziridinecarbonyl chloride, 1-[(4-methylphenyl)sulfonyl]-3-phenyl- (CA INDEX NAME)
MF C16 H14 Cl N O3 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	180.36	587.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

FILE 'CAPLUS' ENTERED AT 12:04:53 ON 13 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Sep 2008 VOL 149 ISS 12

FILE LAST UPDATED: 12 Sep 2008 (20080912/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l9
L10 2 L9

=> d 1-2 bib abs

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:979631 CAPLUS
DN 143:267122
TI Semi-synthesis of taxane intermediates and aziridine analogs and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.; Phytogen Inc.
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005082875	A2	20050909	WO 2005-US5953	20050224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050192445	A1	20050901	US 2004-790622	20040301
	CA 2598707	A1	20050909	CA 2005-2598707	20050224
	EP 1732911	A2	20061220	EP 2005-723708	20050224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1942458	A	20070404	CN 2005-80008412	20050224
	US 20080033189	A1	20080207	US 2007-590647	20070720
PRAI	US 2004-785422	A	20040224		
	US 2004-790622	A	20040301		
	WO 2005-US5953	W	20050224		

OS CASREACT 143:267122; MARPAT 143:267122
GI



I



II

AB A process is provided for the semi-synthesis of taxane intermediates I [R = H, O-protecting group] and aziridine analogs II of cephalomannine and intermediates of baccatin III , and the conversion of such intermediates and analogs to paclitaxel and docetaxel. One process comprises: (a) conversion of the side chain of cephalomannine to an aziridine; (b) hydrolysis of the side chain. Another process comprises: (a) preparation of N-tosyl-3-phenylaziridine-3-carbonyl chloride or 2-acetoxy-3-phenyl-3-(tosylamino)propionyl chloride from cinnamoyl chloride; (b) acylation of 7-O-protected baccatin III by the carbonyl chlorides; and (c) acetolysis followed by hydrolysis of the former or hydrolysis of the latter intermediate. A third process comprises: (a) epoxidn. of the side chain of cephalomannine; (b) azidolysis of the side chain epoxide; (c) hydrolysi of the side chain.

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:963841 CAPLUS
DN 143:248536
TI Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
IN Naidu, Ragina
PA Phytogen Life Sciences Inc., Can.
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050192445	A1	20050901	US 2004-790622	20040301
	CA 2598707	A1	20050909	CA 2005-2598707	20050224

```
     WO 2005082875        A2    20050909    WO 2005-US5953         20050224
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
              SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
              RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
              MR, NE, SN, TD, TG
     EP 1732911           A2    20061220    EP 2005-723708         20050224
          R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     CN 1942458           A     20070404    CN 2005-80008412       20050224
     US 20070027331       A1    20070201    US 2006-372476         20060309
     US 20080033189       A1    20080207    US 2007-590647         20070720
PRAI US 2004-785422       A     20040224
     US 2004-790622       A     20040301
     WO 2005-US5953       W     20050224
OS   CASREACT 143:248536; MARPAT 143:248536
GI
```



I

AB A process is provided for the semi-synthesis of taxane intermediates and aziridine analogs (e.g. formula I [R = H, protecting group]) of cephalomannine and baccatin III intermediates, and the conversion of such intermediates and analogs to paclitaxel and docetaxel (no data).

```
=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY     SESSION
FULL ESTIMATED COST                               6.30      594.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
```

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.60	-9.60

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:05:39 ON 13 SEP 2008